Abacavir 300mg
Product Overview
| Generic Name | Abacavir 300mg |
| Brand Name(s) | Ziagen®, Abamune, Trizivir (combination), Abec |
| Category | Antivirals - Antiretrovirals |
| Form | 60 Film-coated tablets; oral use |
| Strength | 300mg |
| Therapeutic Class | Nucleoside reverse transcriptase inhibitor |
| ATC Code | J05AR01 |
Manufacturing & Regulatory
| Manufacturer | Multiple |
| GMP Compliance | WHO/cGMP-compliant |
| DMF/CEP | Type II |
| COFEPRIS | 010.000.4273.00 |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 packs |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C (room temperature), keep dry/cool |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Provided per batch |
| SDS-Safety Data Sheet (PDF) | MSDS per international standards |
| CTD Summary (PDF) | available from WHO‑GMP manufacturers upon significant orders |
Special Notes
Indicated for the treatment of HIV‑1 infection, to be used as part of combination antiretroviral therapy. It inhibits reverse transcriptase, preventing viral DNA synthesis. Not recommended for patients positive for HLA‑B*5701 allele due to risk of hypersensitivity.